Skip to Main Content

Paper Details

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.
JCI Insight
10
2021
CDK4, KRAS, KRAS-mutant lung cancer, MEK, cyclin-dependent kinase 4, mesenchymal cancer, mesenchymal cancer cells, mesenchymal tumor, mesenchymal tumor cells, p21, patients, tumor, tumor cell subpopulations, tumor cell subsets, tumor subpopulations, tumors, zinc, zinc finger E-box binding homeobox 1

Datasets

Release 1.2